. Author manuscript; available in PMC: 2019 Nov 1.

Published in final edited form as: Breast J. 2018 Sep 27;24(6):1126–1128. doi: 10.1111/tbj.13128

Table 1.

Demographic and Treatment History of each Participant

	Mary	Kate	Ally
Age	28	24	27
BC Type	IDC	IDC	IDC
Stage	3a	3c	3a
Receptor St	ER+/PR+/HER2+	ER-/Pr-/HER+	ER+/PR+/HER2+
Treatment	Rx, Db Mast., Doxorubicin chemo	Db Mast.,Taxol chemo	Rx, Db Mast., Doxorubicin chemo
Yrs Education	15	16.5	16.5
Employment	Full time	Full time	Full time
Ethnicity	White/Hispanic	White/Non-Hispanic	White/Non-Hispanic

Note: IDC: invasive ductal carcinoma; ER: estrogen; PR: progesterone; HER2: human epidermal growth factor receptor 2; Rx: radiation therapy; Db Mast: double mastectomy; chemo: chemotherapy treatment